A single-center, real-world retrospective study evaluated the role of G-CSF prophylaxis in 85 patients diagnosed with NHL and chronic lymphocytic leukemia, treated with bendamustine–rituximab. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.